Innovative therapies for advanced ovarian cancer

Seminars in Oncology

Volumn 27, Issue 3 SUPPL. 7, 2000, Pages 24-30

  Trimble, E L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE ANTIBIOTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; THIOTEPA; TOPOTECAN; VINCRISTINE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG FORMULATION; DRUG MECHANISM; FEMALE; GENE THERAPY; HUMAN; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS; FEMALE; GENE THERAPY; HUMANS; OVARIAN NEOPLASMS; SALVAGE THERAPY;

EID: 0033883259     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Ongoing and unsaid on oxaliplatin: The hope
2. A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) and/or taxanes (TX) pretreated advanced ovarian cancer (AOC): Final results
3. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
4. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line
5. Oxaliplatin: A review of preclinical and clinical studies
6. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
7. The role of anthracyclines in epithelial ovarian cancer
8. Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin
9. Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma
10. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group
11. Epirubicin/paclitaxel/carboplatin as first-line treatment in ovarian cancer: Results of a safety interim analysis of the AGO-GINECO Inter-group trial
12. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers
13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
14. Interim analysis of a non-comparative, multicenter study of DOXIL/CAELYX in the treatment of patients with refractory ovarian cancer
15. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): Results from three consecutive phase I/II studies
16. Phase III, randomized, open-label, comparative study of liposomal doxorubicin (DOXIL) versus topotecan HCI in patients with epithelial ovarian carcinoma following failure of first line, platinum based chemotherapy
17. Phase I study of doxorubicin HCI liposome and prolonged etoposide as second line therapy in patients with recurrent or persistent ovarian, tubal, and peritoneal carcinoma
18. A phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer: A New York gynecologic oncology group (NYGOG) study
19. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
20. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
21. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
22. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma
23. Lower dose Hycamtin as effective as labeled dose with less toxicity in patients with recurrent ovarian cancer
24. Phase I study of paclitaxel, cisplatin, and topotecan with or without filgrastim (G-CSF) in patients with newly diagnosed advanced ovarian cancer
25. Phase I study of gemcitabine and topotecan in patients with refractory or recurrent ovarian or fallopian tube cancer
26. Phase I study of sequential prolonged topotecan and prolonged etoposide as second line therapy in patients with recurrent ovarian epithelial, peritoneal, or tubal cancer
27. Phase II study of high dose sequential paclitaxel, carboplatin, and topotecan with peripheral blood stem cell transplantation in patients with suboptimally debulked stage III or IV ovarian, fallopian tube, or peritoneal carcinoma
28. Phase II study of high dose carboplatin, paclitaxel, and topotecan as initial chemotherapy with autologous peripheral blood stem cell transplantation in patients with optimally debulked stage III ovarian carcinoma
29. Phase I/II study of high dose topotecan, mitoxantrone, and thiotepa with autologous peripheral blood stem cell transplantation for recurrent or refractory platinum resistant ovarian cancer
30. Phase I/II study of topotecan as a component of multicourse high dose chemotherapy with peripheral blood stem cell support for recurrent or persistent ovarian epithelial cancer
31. Sequential couplets of cisplatin (DDP)/topotecan (TOP) and cisplatin/paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer (EOC): An NCIC Clinical Trials Group phase II study
32. Sequential Hycamtin following paclitaxel and carboplatin in advanced ovarian cancer
33. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
34. Sequential topotecan (T) and etoposide (E) in pretreated ovarian cancer patients: A GINECO phase II study
35. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process
36. The role of gemcitabine in the treatment of ovarian cancer
37. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures
38. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
39. Phase I study of docetaxel, carboplatin, and gemcitabine in patients with previously untreated, newly diagnosed, high risk epithelial tumors of mullerian origin
40. Phase II study of weekly paclitaxel and gemcitabine in patients with platinum-resistant ovarian cancer
41. Phase I study of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated ovarian epithelial cancer or primary peritoneal cancer
42. Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma
43. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV
44. Human ovarian cancer xenografts in nude mice: Chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride
45. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease
46. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
47. Navelbine in advanced ovarian epithelial cancer: A study of the French oncology centers
48. A phase II trial of vinorelbine in relapsed and refractory ovarian cancer: A Southwest Oncology Group study (SWOG-9324)
49. Schedule-dependent interactions between vinorelbine and paclitaxel human carcinoma cell lines in vitro
50. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
51. Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study
52. Intraperitoneal interferon-α in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study
53. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: A Gynecologic Oncology Group study
54. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer
55. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study
56. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer - Long-term follow-up
57. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer
58. Intraperitoneal therapy of ovarian cancer
59. Phase I and pharmacokinetic study of intraperitoneal topotecan
60. A phase I trial of intraperitoneal (IP) cisplatin with IP gemcitabine in patients (Pts) with epithelial ovarian cancer
61. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse
62. Adenovirus-based p53 gene therapy in ovarian cancer
63. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer
64. Phase I study of adenovirus mediated HSV-TK gene therapy followed by concomitant chemotherapy with topotecan after optimal debulking surgery for recurrent ovarian cancer
65. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase selectively sensitizes human ovarian carcinoma cells to ganciclovir
66. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
67. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
68. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts
69. The prognostic significance of angiogenesis in epithelial ovarian carcinoma
70. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer
71. Clinical investigation of a cytostatic calcium influx, inhibitor in patients with refractory cancers
72. Phase II study of CAI in patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer